Daré Bioscience, Inc. (DARE) Financial Analysis & Valuation | Quarter Chart
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product in... more
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, devel... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $11.57M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Sabrina Martucci Johnson |
| IPO Date | 2014-04-10 | CAGR | 9.08% |
| Employees | 23 | Website | www.darebioscience.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
DARE chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $10.86M | P/E | -1.1 | Forward P/E | -1.9 | PEG | — |
| P/S | 0.01 | P/B | -0.01 | P/CF | -0.01 | P/FCF | -0.01 |
| Sales | $1.37M | Sales 1Y | -7816.73% | Sales 3Y | inf% | Sales 5Y | inf% |
| EPS | $-0.7 | EPS 1Y | -63.28% | EPS 3Y | -86.08% | EPS 5Y | -7.13% |
| Sales QoQ | 23.02% | EPS QoQ | -4.76% | Sales QoQ Avg | 11245.64% | EPS QoQ Avg | 1.06% |
| Gross Margin | -89.45% | Operating Margin | -813.38% | Profit Margin | -804.37% | ROCE | -203.95% |
| ROA | -49% | ROE | -748% | Altman Z Score | -13.42 | Piotroski Score | 2 |
| Current Ratio | 0.99 | Quick Ratio | 0.99 | Cash Ratio | 0.75 | Op. CF Ratio | -0.4 |
| Debt/Equity | -1.82 | Debt/Assets | 0.05 | Lt Debt/Equity | -0.49 | Lt Debt/Cap. | -0.96 |
| Intrst Cov. | -55.72 | Inventory Turnover | — | Asset Turnover | 0.06 | Receivables Turnover | 2.99 |
| Enterprise Value | $10.86M | P/E Ratio | -1.1 |
| Forward P/E | -1.9 | PEG Ratio | — |
| P/S Ratio | 0.01 | P/B Ratio | -0.01 |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $-0.7 | EPS Growth 1Y | -63.28% |
| EPS Growth 3Y | -86.08% | EPS Growth 5Y | -7.13% |
| Revenue Growth 1Y | -7816.73% | Gross Margin | -89.45% |
| Operating Margin | -813.38% | Profit Margin | -804.37% |
| ROE | -748% | ROA | -49% |
| ROCE | -203.95% | Current Ratio | 0.99 |
| Quick Ratio | 0.99 | Cash Ratio | 0.75 |
| Debt/Equity | -1.82 | Interest Coverage | -55.72 |
| Altman Z Score | -13.42 | Piotroski Score | 2 |
Daré Bioscience, Inc. (DARE) valuation & financials
Daré Bioscience, Inc. (DARE) has a market capitalization of $11.57M and trades at a price-to-earnings ratio of -1.1. It operates in the Healthcare sector (Biotechnology).
Daré Bioscience, Inc.'s revenue grew -7816.7% over the last year.
Daré Bioscience, Inc.'s next earnings report is scheduled for November 12, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.14. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)